The US-based CDMO will use the joint funds to strengthen its capability and capacity to produce the next generation of green pressurised metered-dose inhalers
Kindeva secures industry and government investment of £33m for green inhaler manufacturing. (Credit: Bob Williams from Pixabay)
Kindeva Drug Delivery has secured a grant from the UK Government’s Life Sciences Innovation Manufacturing Fund (LSIMF) that has unlocked an investment of £33m to boost the production and sustainability of inhalers.
The US-based drug delivery device contract development and manufacturing organisation (CDMO) will use the joint funds to strengthen its capability and capacity to produce the next generation of green pressurised metered-dose inhalers (pMDIs).
In addition, the funds will be used to continue the supply of ever-evolving respiratory illness medicines globally.
The investment backs the worldwide advancement and production of inhalers utilising novel propellants with reduced global warming potential (GWP).
According to the CDMO, it will create and preserve local jobs at the company’s two UK locations, Loughborough and Clitheroe.
Additionally, the industry and government investment also supports new manufacturing capability and capacity in Loughborough for the next generation of green inhalers.
The investment will contribute to the green improvements of Kindeva’s foundational inhaler component supply chain at the Clitheroe site.
Kindeva global chief commercial officer David Stevens said: “This joint investment of public and private funds creates myriad new opportunities for Kindeva colleagues within the UK, as significant technical and regulatory expertise is required in the development and manufacturing of complex inhalation products.
“This investment provides Kindeva with a springboard to expand our capabilities and capacity, while simultaneously partnering with leading pharmaceutical companies around the world to bring the next generation of green inhalers to market — with a common goal of safeguarding access to necessary therapies for patients and reducing our impact on the planet.”
Kindeva said that the investment will help pharmaceutical companies as they make green transitions with existing products. It enables them to launch new green inhalers and respiratory therapies for patients.
The grant marks the sixth investment facilitated by the LSIMF, which, in the previous fiscal year, provided a combined government and industry support of £340m for life sciences manufacturing in the UK.